32nd Hemophilia Symposium Hamburg 2001
Inge Scharrer, Wolfgang Schramm
Springer Berlin Heidelberg, Oct 23, 2002 - Medical - 318 pages
Seven months following LTX quality of live has increased markedly in the hereby presented patient. A prolonged life expectance can be anticipated due to improved liver function and decreased bleedingtendency as a result of elevated leukocyte and thrombocyte counts. A positive surprise is the patients comment of less joint pain in spite of unchanged hemophilic arthropathy. If this is also true for other haemo philia patients following LTX this may develop as a new objective towards gene therapy as well. From a clinical perspective bleeding risk ismarkedlyreduced due to nearlynor mal factor VIII and thrombocyte levels as well as a presumable reduction of blood pressure in esophageal varacies. CD4-Helper cells increased significantly after LTX. However,at the same time a decrease of CD4/CD8 ratio was measured. CD4 count alone may therefore not be appropriate for HIV staging or subsequent decision whether or not immunfunction is sufficient for later LTX. Due to a CD4 count of above 700following livertransplantations the risk of opportunistic infections islow at this time. According to these preliminary results LTX should be considered in a subgroup of haemophilia patients with advanced liver cirrhosis in spite of HIV infection. Dysfibrinogenemia following after Snake Bite M. KRAUSE, J. BOJUNGA, D. MEBS, and I. SCHARRER Introduction A 35 year old snake breeder was bitten on the left foot by a middle American pit viper Crotalus durissus dryinas which had escaped.
What people are saying - Write a review
We haven't found any reviews in the usual places.
HIV Infection and Causes of Death in Patients with Hemophilia in Germany
A first Insight
Greifswald Registry FIX Deficiency
19 other sections not shown
Other editions - View all
32nd Hemophilia Symposion Abteilung acute analysis antibodies antigen assay Berlin Heidelberg 2003 bleeding cell lines Ciprofloxacin clinical clotting coagulation factor concentrations coronary detected disease dose eptifibatide exon expression factor IX factor IX gene factor VIII factor VIII inhibitors factor XI deficiency fibrinolysis Frau Dr FVII FVIII G G G gene therapy genetic genomic Hamatologie Hamostaseologie hematopoietic cells hemophilia Hemophilia Symposion Hamburg heparin Herrmann FH heterozygous hFIX human factor VIII immune tolerance infection intron joints Klinik Klinikum levels LMWH low coagulant challenge Medizinische methods moderate molecular ng/ml normal patients pediatric plasma platelet platelet aggregation polymorphisms Prof protein prothrombin recombinant risk factors Scharrer Scharrer/W Schramm sequence Springer-Verlag Berlin Heidelberg Symposion Hamburg 2001 Table TFPI Thromb Haemost thrombin thromboembolic thrombophilia thrombotic thrombotic thrombocytopenic purpura Transfusionsmedizin treatment vCJD vector venous thrombosis vitro von-Willebrand vWF:Ag vWFcp activity Willebrand Wulff